COMP <GO>
ETON vs PCRX // EV/EBITDA & P/E VALUATION
Eton Pharmaceuticals Inc. (NASDAQ) VS. Pacira BioSciences Inc. (NASDAQ) • 15-METRIC TALLY: ETON 3
— PCRX 7
■ METRIC PARITY
LAST: $50.81 (-2.63%) • MKT CAP: $1.49B
valuation
—
LAST: $36.40 (+0.03%) • MKT CAP: $1.45B
valuation
51.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ETON VS. PCRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ETON | PCRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.50% | 79.40% | -25.90 | PCRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -0.90% | 1.70% | -2.60 | PCRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 51.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.66% | 9.42% | -8.76 | PCRX | /fcf-yield <GO> |
| Operating Margin | -1.10% | 2.60% | -3.70 | PCRX | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 1.00% | -6.80 | PCRX | /net-margins <GO> |
| Revenue Growth (YoY) | 104.90% | 3.60% | +101.30 | ETON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.37 | 2.33 | +11.04 | ETON | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | PCRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 83.2 | -35.30 | PCRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.49B | $1.45B | $40.9M | ETON | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ETON REV | PCRX REV | ETON GROSS % | PCRX GROSS % | ETON FCF | PCRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $80.0M | $726.4M | 53.5% | 79.4% | $10.2M | $136.7M |
| FY 2024 | $39.0M | $701.0M | 60.0% | 75.7% | $943.0K | $178.8M |
| FY 2023 | $31.6M | $675.0M | — | — | $6.8M | $154.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ETON // BETA —
PCRX // BETA —